|
Aug 28
|
IMUNON to Host R&D Day on September 18th
|
|
Aug 14
|
IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update
|
|
Aug 7
|
IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024
|
|
Jul 30
|
Top Midday Gainers
|
|
Jul 30
|
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001
|
|
Jul 29
|
IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow
|
|
Jun 24
|
IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer
|
|
Feb 22
|
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
|
|
Dec 11
|
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Oct 23
|
IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines Congress
|
|
Oct 19
|
IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations
|
|
Oct 18
|
IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer
|
|
Aug 11
|
Q2 2023 Imunon Inc Earnings Call
|
|
Aug 10
|
IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update
|
|
Aug 7
|
Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv
|